Correlations of Visfatin with Severity of Acute Myocardial Infarction, Cardiovascular Risk Factors and Atrial Fibrillation After PCI
Visfatin in Atrial Fibrillation After PCI
Abstract
Background: To investigate the relationship between visfatin level in the peripheral blood of patients with acute myocardial infarction (AMI) patients and the severity of AMI, cardiovascular risk factors and atrial fibrillation after percutaneous coronary intervention (PCI).
Methods: A total of 37 AMI patients diagnosed and treated in our hospital were selected as experimental group, and 35 patients with normal coronary angiography were enrolled as control group. The general pathological data and occurrence of atrial fibrillation after PCI of all the patients were recorded in detail, and the content of indexes related to the severity of AMI and visfatin was measured. Moreover, the correlations of visfatin with the severity of AMI, cardiovascular risk factors and atrial fibrillation after PCI were explored.
Results: The differences in the levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI), myoglobin (MYO) and creatine kinase isoenzyme MB mass (CK-MBm) in the peripheral blood, left ventricular end-systolic diameter (LVEDs), left ventricular end-diastolic volume (LVEDV) and left ventricular ejection fraction (LVEF) were statistically significant between experimental group and control group. Furthermore, experimental group had a remarkably higher visfatin level in the peripheral blood than control group. The visfatin level in the peripheral blood was positively correlated with the severity of AMI and the cardiovascular risk factors, but it was negatively associated with atrial fibrillation after PCI.
Conclusion: The visfatin level in the peripheral blood of AMI patients has close correlations with the severity of AMI, cardiovascular risk factors and atrial fibrillation after PCI.
References
1. Sorensen NA, Donmez G, Neumann JT, Nikorowitsch J, Rubsamen N, Blankenberg S, et al. Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Addition to High-Sensitivity Troponin I in Early Diagnosis of Acute Myocardial Infarction. Biomolecules 2019; 9(3): 108.
2. Hofer F, Kazem N, Hammer A, El-Hamid F, Koller L, Niessner A, et al. Long-Term Prognosis of De-Novo Atrial Fibrillation during Acute Myocardial Infarction - The Impact of Anti-Thrombotic Treatment Strategies. Eur Heart J-Card Pha 2021; 7(3): 189-95.
3. Demirkiran A, Zorkun C, Demir HD, Topcu B, Emre E, Ozdemir N. Relationship between the infarct localization and left ventricular rotation parameters following acute ST-segment elevation myocardial infarction. Turk Kardiyol Dern a 2020; 48(3): 255-62.
4. Kapur NK, Thayer KL, Zweck E. Cardiogenic Shock in the Setting of Acute Myocardial Infarction. Methodist Debakey Cardiovasc J 2020; 16(1): 16-21.
5. Minukhina DV, Babadjan VD, Minukhin DV, Yevtushenko DA, Tverezovskyi MV, Kudrevych OM. Time course of endothelial dysfunction and atherothrombosis markers in patients with acute myocardial infarction with st segment elevation and type 2 diabetes mellitus depending on reperfusion therapy approach. Wiad Lek 2020; 73(1): 123-7.
6. Ragino YI, Stakhneva EM, Polonskaya YV, Kashtanova EV. The Role of Secretory Activity Molecules of Visceral Adipocytes in Abdominal Obesity in the Development of Cardiovascular Disease: A Review. Biomolecules 2020; 10(3): 374.
7. Torretta S, Colombo G, Travelli C, Boumya S, Lim D, Genazzani AA, et al. The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5). Cells-Basel 2020; 9(2): 496.
8. Astrom A, Soderstrom L, Mooe T. Risk of Ischemic Stroke After Acute Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery. Sci Rep-Uk 2020; 10(1): 3831.
9. De Luca L, Savonitto S. Composite trends of cardiogenic shock complicating acute myocardial infarction. Eur J Heart Fail 2020; 22(4): 673-5.
10. Lai XL, Liu HX, Hu X, Tian JF, Shang JJ, Li X, et al. Acute Myocardial Infarction in Chinese Medicine Hospitals in China from 2006 to 2013: An Analysis of 2311 Patients from Hospital Data. Chin J Integr Med 2021; 27(5): 323-9.
11. Ji C, Cong R, Wang Y, Wang Y, Zhang Q, Zhou X, et al. Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis. Ann Transl Med 2019; 7(23): 785.
12. Chyl-Surdacka KM, Bartosinska J, Kowal M, Przepiorka-Kosinska J, Krasowska D, Chodorowska G. Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities. Adv Clin Exp Med 2020; 29(1): 79-84.
13. Sarak T, Karadeniz M. The relationship between serum NT-proBNP levels and severity of coronary artery disease assessed by SYNTAX score in patients with acute myocardial infarction. Turk J Med Sci 2019; 49(5): 1366-73.
14. Hung WC, Yu TH, Hsu CC, Lu LF, Chung FM, Tsai IT, et al. Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction. Clin Invest Med 2015; 38(3): E100-9.
15. Huang P, Riordan SM, Heruth DP, Grigoryev DN, Zhang LQ, Ye SQ. A critical role of nicotinamide phosphoribosyltransferase in human telomerase reverse transcriptase induction by resveratrol in aortic smooth muscle cells. Oncotarget 2015; 6(13): 10812-24.
16. Yamamoto K, Sakakura K, Akashi N, Watanabe Y, Noguchi M, Seguchi M, et al. Novel Acute Myocardial Infarction Risk Stratification (nARS) System Reduces the Length of Hospitalization for Acute Myocardial Infarction. Circ J 2019; 83(5): 1039-46.
17. Chiu CA, Yu TH, Hung WC, Lu LF, Chung FM, Tsai IT, et al. Increased expression of visfatin in monocytes and macrophages in male acute myocardial infarction patients. Mediat Inflamm 2012; 2012: 469852.
18. Zhang H, Dong P, Yang X, Du L, Wang K, Yan P, et al. Prognostic indicators of new onset atrial fibrillation in patients with acute coronary syndrome. Clin Cardiol 2020; 43(6): 647-51.
19. Chan YH, Chang GJ, Lai YJ, Chen WJ, Chang SH, Hung LM, et al. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. Cardiovasc Diabetol 2019; 18(1): 125.
20. Platek AE, Szymanska A, Kalaszczynska I, Szymanski FM, Sierdzinski J, Filipiak KJ. Usefulness of Visfatin as a Predictor of Atrial Fibrillation Recurrence After Ablation Procedure. Am J Cardiol 2020; 125(3): 415-9.
Copyright (c) 2023 Huihui Zhang, Dingwei Lei, Miaolin Zhang, Sijia Tu, Chaofeng Shen, Fengxian Lin
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.